A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against damage caused by ultraviolet irradiation - 24/04/13
Reprint requests: Sheldon R. Pinnell, MD, M3135 Duke University Medical Center, Durham, NC 27710.Abstract |
Background |
Skin cancer and photoaging changes result from ultraviolet (UV)-induced oxidative stress. Topical antioxidants may protect skin from these effects.
Objective |
We sought to determine whether a stable topical formulation of 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid (CEFer) could protect human skin in vivo from substantial amounts of solar-simulated UV radiation.
Methods |
CEFer and its vehicle were applied to separate patches of normal-appearing human skin for 4 days. Each patch was irradiated with solar-simulated UV, 2 to 10 minimal erythema doses, at 2-minimal erythema dose intervals. One day later, skin was evaluated for erythema and sunburn cells, and immunohistochemically for thymine dimers and p53. UV-induced cytokine formation, including interleukin (IL)-1⍺, IL-6, IL-8, and IL-10, and tumor necrosis factor-⍺, were evaluated by real-time polymerase chain reaction.
Results |
CEFer provided significant and meaningful photoprotection for skin by all methods of evaluation.
Limitations |
The number of patients evaluated was relatively small.
Conclusion |
CEFer provided substantial UV photoprotection for skin. It is particularly effective for reducing thymine dimer mutations known to be associated with skin cancer. Its mechanism of action is different from sunscreens and would be expected to supplement the sun protection provided by sunscreens.
Le texte complet de cet article est disponible en PDF.Abbreviations used : cDNA, CEFer, IL, MED, mRNA, PBS, PCR, RT, TNF, UV
Plan
| Supported by a grant from SkinCeuticals-L’Oreal, New York, NY. |
|
| Disclosure: Dr Pinnell is a consultant for SkinCeuticals-L’Oreal. Dr Murray, Mr Burch, Mr Streilein, Ms Iannacchione, and Dr Hall have no conflicts of interest to declare. C E Ferulic is a patented formulation, US Patent No. 7,179,841 issued to SkinCeuticals. |
Vol 59 - N° 3
P. 418-425 - septembre 2008 Retour au numéro
Article précédent
- Volunteers Needed
- The value of patch testing patients with a scattered generalized distribution of dermatitis: Retrospective cross-sectional analyses of North American Contact Dermatitis Group data, 2001 to 2004
- Kathryn A. Zug, Robert L. Rietschel, Erin M. Warshaw, Donald V. Belsito, James S. Taylor, Howard I. Maibach, C.G. Toby Mathias, Joseph F. Fowler, James G. Marks, Vincent A. DeLeo, Melanie D. Pratt, Denis Sasseville, Frances J. Storrs
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?